Pfizer Inc. / Vivet Therapeutics S.A.S.

Wilson Disease

600 US cases/yr · $350M Global Wilson disease therapeutics market 2022 · ~8,000-12,000 U.S. prevalent patient pool with Wilson disease

Disease Overview

Wilson disease is a rare autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene, which encodes a copper-transporting P-type ATPase essential for hepatic copper excretion into bile. Loss-of-function mutations cause progressive copper accumulation in the liver, brain, and other organs, leading to hepatic failure, neurological deterioration (dystonia, dysarthria, parkinsonism), and Kayser-Fleischer corneal rings. U.S. prevalence is approximately 8,000-12,000 patients (~1 in 30,000), with an estimated 600 new diagnoses annually. Symptoms typically present between ages 5 and 35. Standard of care is lifelong copper chelation with penicillamine (Cuprimine), trientine (Syprine, Cuprior), or zinc salts (Galzin) — all small molecules that manage but do not cure. Liver transplant remains the rescue therapy for fulminant hepatic failure. Vivet's VTX-801 is an AAV (adeno-associated virus) gene therapy delivering a functional ATP7B mini-gene to hepatocytes, designed as a one-time curative intervention. The Pfizer manufacturing agreement supports the GATEWAY Phase 1/2 trial. Pricing benchmarks for AAV liver-directed gene therapies range from BioMarin's Roctavian (hemophilia A, $2.9M list, withdrawn from U.S. 2025) to PTC's Upstaza (AADC deficiency, ~$3.5M ex-U.S.), supporting a multi-billion dollar peak commercial opportunity in a chronic, progressive rare disease.

Competitive Landscape

The Wilson disease competitive landscape splits between long-tenured copper-chelation small molecules and an emerging gene therapy and disease-modifying class. Standard of care is dominated by Cuprimine (penicillamine, copper chelator, ~70-year history), Syprine and generic trientine (copper chelator), Cuprior (trientine tetrahydrochloride, Univar Solutions/Orphalan), and Galzin (zinc acetate, Teva, copper absorption inhibitor). Alexion/AstraZeneca's ALXN1840 (bis-choline tetrathiomolybdate, oral copper-binding agent) is in Phase 3 (FoCus trial) as a potential next-generation chelator. Vivet/Pfizer's VTX-801 (AAV-anc80-ATP7B) is the lead AAV liver-directed gene therapy in Phase 1/2 (GATEWAY). Other gene therapy entrants include Ultragenyx's UX701 (AAV-ATP7B) in Phase 1/2 Cyprus2+ trial. Adjacent disease-modifying approaches include methanobactin therapeutics (preclinical, multiple academic groups). For Pfizer, the Vivet manufacturing agreement extends a strategic 2019 minority equity stake plus exclusive option to acquire, positioning Pfizer alongside Ultragenyx as the two large-pharma anchors in Wilson disease gene therapy. The deal modality (manufacturing supply rather than licensing) reflects Pfizer's preference for staged optionality given the early Phase 1/2 stage of VTX-801.